Page 2 - Breast Unit News Today

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Bolton is being lit up pink this month to mark the significance of Breast Cancer Awareness month

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that new data was presented at the European Society of Breast Imaging ("EUSOBI") Scientific Meeting in Valencia, Spain by Lucía Graña-López, MD, PhD, principal investigator of the independent, non-sponsored stu...

Growing body of evidence-based data is giving women a minimally invasive alternative to the standard of care lumpectomyPatients throughout the European Union have access to ProSense for the...

Royal Bolton Hospital has been named one of the UK’s first ‘Centres of Excellence’ for care.

A breast cancer survivor has thanked the Breast Unit in Bolton for the ‘phenomenal’ care she has received.

Triumphant cyclists who travelled more than 100 miles from Wiltshire to Devon managed to raise a huge sum of money following a diagnosis of breast…

BBC presenter Mari Grug has been undergoing chemotherapy following her unexpected breast cancer diagnosis.

The trial was recommended to continue to analyze event-free survival rates, but current results are encouraging for treating estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Pembrolizumab plus chemotherapy led to significant improvement in pathological complete response rate for high-risk, early-stage ER+/HER2- breast cancer.